Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Baker

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2000
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxelC D Britten, S D Baker, L J Denis, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Clinical and Translational Science|February 5, 2016
ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and MyelosuppressionC D Drenberg, S Hu, L Li, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2003
Phase I trial of continuous infusion 5-aza-2'-deoxycytidineA Aparicio, C A Eads, L A Leong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemiaF J Giles, J E Cortes, S D Baker, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 8, 2001
Tumor targeting by conjugation of DHA to paclitaxelM O Bradley, C S Swindell, F H Anthony, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2022
The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321J Gartrell, J C Panetta, S D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusionS O'Reilly, S D Baker, S Sartorius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1996
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemiaE K Rowinsky, S H Kaufmann, S D Baker, et al.
Clinical Pharmacology and Therapeutics|January 10, 2008
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurementsA C Hooker, A J Ten Tije, M A Carducci, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2000
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxelC D Britten, S D Baker, L J Denis, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Clinical and Translational Science|February 5, 2016
ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and MyelosuppressionC D Drenberg, S Hu, L Li, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2003
Phase I trial of continuous infusion 5-aza-2'-deoxycytidineA Aparicio, C A Eads, L A Leong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemiaF J Giles, J E Cortes, S D Baker, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 8, 2001
Tumor targeting by conjugation of DHA to paclitaxelM O Bradley, C S Swindell, F H Anthony, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2022
The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321J Gartrell, J C Panetta, S D Baker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusionS O'Reilly, S D Baker, S Sartorius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1996
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemiaE K Rowinsky, S H Kaufmann, S D Baker, et al.
Clinical Pharmacology and Therapeutics|January 10, 2008
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurementsA C Hooker, A J Ten Tije, M A Carducci, et al.
Pageof 7